
Date Published: May 2, 2020
Source: BBC News
Remdesivir, a drug initially developed to treat Ebola, has been given the emergency green-light by the FDA for emergency use of the drug in the treatment of COVID-19. A recent clinical trial demonstrated that remdesivir reduced duration of symptoms from 15 days to 11, but did not significantly improve survival rates. 1.5 million vials of the drug are being donated to hospitals in cities in the US most heavily impacted by COVID-19, but supply is limited. Gilead, the pharmaceutical company producing the drug, aims to increase production and have one million treatment courses produced by the end of the year.
Read the full article here: https://www.bbc.com/news/world-us-canada-52511270
Summary by: Megan Lam